WO2012088146A3 - Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease - Google Patents

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease Download PDF

Info

Publication number
WO2012088146A3
WO2012088146A3 PCT/US2011/066233 US2011066233W WO2012088146A3 WO 2012088146 A3 WO2012088146 A3 WO 2012088146A3 US 2011066233 W US2011066233 W US 2011066233W WO 2012088146 A3 WO2012088146 A3 WO 2012088146A3
Authority
WO
WIPO (PCT)
Prior art keywords
colon cancer
cancer disease
nox4
lcc
rcc
Prior art date
Application number
PCT/US2011/066233
Other languages
French (fr)
Other versions
WO2012088146A2 (en
Inventor
Steven Buechler
Amanda B. HUMMON
Original Assignee
The University Of Notre Dame
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Notre Dame filed Critical The University Of Notre Dame
Priority to EP11850360.6A priority Critical patent/EP2655663A4/en
Publication of WO2012088146A2 publication Critical patent/WO2012088146A2/en
Publication of WO2012088146A3 publication Critical patent/WO2012088146A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)
    • C12Y106/03—Oxidoreductases acting on NADH or NADPH (1.6) with oxygen as acceptor (1.6.3)
    • C12Y106/03001—NAD(P)H oxidase (1.6.3.1), i.e. NOX1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Relapse risk in right-side colon tumors is characterized by accelerated cell cycle progression and elevated Wnt signaling. Left-side colon tumors with reduced Wnt signaling are more relapse prone. The single gene prognostic biomarker indicator for left side (LCC) colon cancer disease is NADPH oxidase 4 (NOX4), MMP3, or a set of both genes. A genetic prognostic biomarker indicator for right side (RCC) colon cancer disease is caudal type homeobox 2 (CDX2), FAM69A, or a set of both genes. NOX4 expression levels in human patients with LCC colon cancer disease is used in patient specific clinical treatment strategies. Colon cancer patients having LCC colon cancer disease where the tumor is found to have a low NOX4 expression level have a high 5- year relapse-free survival probability, while an elevated NOX4 expression level indicates a lower survival probability. CDX2 expression levels in human patients with RCC colon cancer disease is used in patient specific clinical treatment strategies. In RCC colon cancer disease, an elevated CDX2 expression level indicates a high 5-year relapse survival probability, while lower expression levels indicate a lower 5-year relapse-free survival probability. NOX4 (CDX2) is more prognostic for LCC (RCC) colon cancer treatments. NOX4 is expressed in adenocarcinoma. NOX4 siRNA is shown to cause a significant reduction in reactive oxidative species (ROS) production.
PCT/US2011/066233 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease WO2012088146A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11850360.6A EP2655663A4 (en) 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061459864P 2010-12-20 2010-12-20
US61/459,864 2010-12-20

Publications (2)

Publication Number Publication Date
WO2012088146A2 WO2012088146A2 (en) 2012-06-28
WO2012088146A3 true WO2012088146A3 (en) 2012-10-11

Family

ID=46314850

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/066233 WO2012088146A2 (en) 2010-12-20 2011-12-20 Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Country Status (2)

Country Link
EP (1) EP2655663A4 (en)
WO (1) WO2012088146A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2821507A1 (en) * 2013-07-01 2015-01-07 Centre National de la Recherche Scientifique (CNRS) A method for detecting, identifying and/or quantifying a pathogen in an individual
CN114540499A (en) * 2022-03-17 2022-05-27 郑州源创吉因实业有限公司 Application of model constructed based on PCD related gene combination in preparation of product for predicting colon adenocarcinoma prognosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
US20100136571A1 (en) * 2007-07-19 2010-06-03 Biomerieux I-plastin assay method for the in vitro diagnosis of colorectal cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2430452T3 (en) * 2009-05-14 2014-10-06 Univ Arizona State CARCINOM DIAGNOSIS AND TREATMENTS BASED ON ODC1 GENOTYPE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030186302A1 (en) * 2002-03-29 2003-10-02 Yixin Wang Colorectal cancer diagnostics
US20050014165A1 (en) * 2003-07-18 2005-01-20 California Pacific Medical Center Biomarker panel for colorectal cancer
US20100136571A1 (en) * 2007-07-19 2010-06-03 Biomerieux I-plastin assay method for the in vitro diagnosis of colorectal cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAUER, K. M. ET AL.: "Right-side and left-side colon cancer follow different pathways to relapse", MOLECULAR CARCINOGENESIS, vol. 51, no. 5, 7 June 2011 (2011-06-07), pages 411 - 421, XP055073577 *
BRENNER, H. ET AL.: "Protection from right- and left-sided colorectal neoplasms after colonoscopy: Population-based study", J. NATL. CANCER INST., vol. 102, 30 December 2009 (2009-12-30), pages 89 - 95, XP055073576 *
PARK, H. S. ET AL.: "Impaired generation of reactive oxygen species in leprechaunism through downregulation of Nox4", DIABETES, vol. 54, no. 11, November 2005 (2005-11-01), pages 3175 - 3181, XP055073574 *
See also references of EP2655663A4 *

Also Published As

Publication number Publication date
WO2012088146A2 (en) 2012-06-28
EP2655663A4 (en) 2015-01-28
EP2655663A2 (en) 2013-10-30

Similar Documents

Publication Publication Date Title
Guo et al. m6A reader HNRNPA2B1 promotes esophageal cancer progression via up-regulation of ACLY and ACC1
Sun et al. Association of decreased expression of serum miR-9 with poor prognosis of oral squamous cell carcinoma patients
Hu et al. Expression patterns of USP22 and potential targets BMI-1, PTEN, p-AKT in non-small-cell lung cancer
Liu et al. Berberine inhibits the metastatic ability of prostate cancer cells by suppressing epithelial-to-mesenchymal transition (EMT)-associated genes with predictive and prognostic relevance
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
Chen et al. Long non-coding RNA CCHE1 overexpression predicts a poor prognosis for cervical cancer
Fang et al. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients
WO2011085263A3 (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Liu et al. Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer
WO2012079059A3 (en) Post-treatment breast cancer prognosis
WO2015052583A3 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
IN2012DN04944A (en)
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
Gu et al. The dual functions of the long noncoding RNA CASC15 in malignancy
WO2005001138A3 (en) Breast cancer survival and recurrence
SG168430A1 (en) Molecular signature of human lung cancer initiating cells
Pourdavoud et al. MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer
Song et al. Current research on head and neck cancer-associated long noncoding RNAs
Rajendiran et al. MicroRNA-940 as a potential serum biomarker for prostate cancer
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
Baygi et al. Deregulation of MTDH gene expression in gastric cancer
Wu et al. Long non-coding RNA Loc344887 is a potential prognostic biomarker in non-small cell lung cancer
WO2012088146A3 (en) Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11850360

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011850360

Country of ref document: EP